November 17, 2026
Clinical Trial Site Feasibility in the EU: What Sponsors Need Under the Clinical Trials Regulation
How site feasibility works for clinical trials in the EU and EEA: the Part II site documents under Regulation 536/2014, what goes into CTIS, and how a site prepares.
Short answer
In the EU and EEA, site feasibility follows the same questionnaire and qualification visit used elsewhere, with one addition: under the Clinical Trials Regulation (EU) 536/2014 the sponsor must file documents about each site and investigator in CTIS. A site that already has its investigator CV, declaration of interests and site suitability form ready is faster to select.
If your practice is in the European Union or the wider EEA, a sponsor assesses your site in much the same way as anywhere else. They want to know whether you have the patients, the people and the facilities to run their protocol. What changes is the paperwork behind that decision. The Clinical Trials Regulation (EU) 536/2014 makes the sponsor file documents about your site and your investigator with the authorities for every trial, so being ready means having those documents in order before anyone asks.
For the general process, start with what site feasibility is. This guide covers what is specific to the EU.
How the EU system is organised
Since the Clinical Trials Regulation took full effect, a sponsor applies for a trial once, through the Clinical Trials Information System (CTIS), for every member state where the trial will run. The application has two parts:
- Part I covers the trial itself: the protocol, the investigational product and the scientific assessment. The member states concerned assess it together.
- Part II covers what is national and local: the consent materials, recruitment arrangements, compensation, and the suitability of each investigator and each site. Each member state assesses its own Part II, with its ethics committee involved.
The practical consequence for a site is simple. You do not submit anything in CTIS yourself, but the sponsor cannot complete Part II for your country without documents that only you can provide.
The site documents a sponsor will ask you for
These are the items sponsors request from EU sites again and again. Having them current is most of what "sponsor-ready" means in Europe.
| Document | What it is | Why it matters |
|---|---|---|
| Investigator CV | A current, signed and dated CV for the Principal Investigator, and often sub-investigators. Most member states expect the European Commission's investigator CV template. | It is part of the Part II dossier for every trial. |
| Declaration of interests | The investigator's statement of financial and other interests in the trial (Annex I of the Regulation). Several countries have their own template. | A missing or late declaration holds up the whole Part II pack. |
| Site suitability form | A short declaration describing your facilities, staff and equipment, signed by the PI or the head of the institution, confirming the site is suitable for this trial. | It is the document that states, formally, what the feasibility questionnaire asked informally. |
| GCP training certificates | Good Clinical Practice certificates for every investigator and study staff member. Sponsors commonly expect them to be under three years old and, for recent training, to reference ICH E6(R3). | Reviewed by the sponsor and, through Part II, by the authorities. |
| Medical registration | Proof of each investigator's current registration with the national medical chamber or regulator. | An expired registration found at qualification can end the conversation. |
| Legal entity details | Registered legal name, company registration number, VAT number, authorised signatory and bank details. | Needed for the clinical trial agreement and for study payments. |
One point on insurance: the sponsor carries the mandatory compensation cover for trial subjects in each member state. Your own professional liability cover should still extend to research activity, and it is worth confirming that with your insurer before contract negotiation starts.
What stays the same as everywhere else
The feasibility questionnaire asks an EU site the same core questions it asks any site:
- How many patients do you see with the target condition, and how many would meet the main criteria?
- Which other trials are you running that draw on the same patients?
- Who coordinates, and how much capacity do they have?
- What facilities, equipment, laboratory and pharmacy arrangements do you have?
- How quickly can you turn around a confidentiality agreement, a questionnaire and a contract?
The site feasibility questionnaire guide walks through each section, and its free template works for EU sites as it stands. Patient counts should be aggregate numbers only. A feasibility answer never needs identifiable patient data, which also keeps the exercise clear of data protection problems.
Finding trials that are open in your country
EU trials authorised under the Regulation are listed publicly in the EU clinical trials register, drawn from CTIS. Each record shows the member states involved and the status in each one, so you can see which trials are recruiting in your country and which sites are already listed. Many large trials also appear on ClinicalTrials.gov, and the two registers do not always carry the same details, so it is worth checking both.
How to prepare, in order
- Name your Principal Investigator and check any national expectations about investigator experience before you approach a sponsor.
- Complete the investigator CV on the European Commission template, signed and dated, and keep it with a review date.
- Get GCP certificates current for everyone who will work on a study.
- Draft a master site suitability form describing your facilities, staff and equipment, so each trial is an adjustment and not a blank page.
- Know each investigator's declaration of interests answers in advance.
- Gather your legal entity and bank details in one place.
- Pull aggregate patient counts by condition from your records, with the date of the query.
Country rules differ in the details. Ethics committee arrangements, templates and investigator experience expectations vary between member states, so confirm the specifics for your own country with your national authority or the sponsor.
Frequently asked questions
Does a site submit anything in CTIS? No. The sponsor makes the application. The site supplies the documents the sponsor needs for Part II, such as the investigator CV, the declaration of interests and the site suitability form.
What is a site suitability form? It is a signed declaration that the site has the facilities, staff and equipment to run a specific trial. It is part of the Part II dossier under Regulation (EU) 536/2014, and many member states publish a template for it.
Is site feasibility in the EU different from the United States? The assessment is the same in substance: patients, people, facilities and speed. The difference is regulatory. In the EU the sponsor files site and investigator documents with the authorities for each trial, where in the United States the investigator signs Form FDA 1572 for drug and biologic studies.
Do EU sites need a different feasibility questionnaire? No. Sponsors use their own questionnaire in every region. EU sites are usually asked a few extra questions about ethics committee arrangements, data protection and legal entity details.
Can a small private practice in the EU run clinical trials? Yes, where it has a qualified investigator, suitable facilities and enough eligible patients. The preparation is mostly documentation, and most of it is done once and then kept current.
TrialWave works for EU and EEA sites: the study finder searches the EU register alongside ClinicalTrials.gov, the readiness checklist follows the Part II documents above, and pricing is available in euros. See which trials are recruiting near you, or read about clinical trial feasibility software for the site side.
This is general information, not legal or regulatory advice. Requirements vary by member state, sponsor and trial. Confirm the specifics with your national competent authority or ethics committee.